Key result
Four weeks of oral enalapril therapy significantly improved endothelium-dependent vasodilation in type I diabetic patients, increasing forearm blood flow by 277% compared to 136% at baseline (P<0.001).
Why the study?
Does enalaprilat and enalapril improve endothelial function in patients with type I diabetes mellitus?
Population
9 male subjects with type I diabetes mellitus without evidence of microvascular or macrovascular…
Comparison
Acute ACE inhibition with intrabrachial… vs Pretreatment baseline and healthy control…
Design
Cohort
Follow-up
4 weeks
Authors
Loading...
Supports endothelial benefit of ACE inhibition in type 1 diabetes; hypothesis-generating and should not yet change practice.
Does enalaprilat and enalapril improve endothelial function in patients with type I diabetes mellitus?
Absolute Event Rate: 277% vs 136%
p-value: p=<0.001
ACE inhibition with enalaprilat and enalapril significantly improves NO-mediated endothelial function in patients with type I diabetes mellitus.
O’Driscoll et al. (1997) studied Type I diabetes mellitus (n=17). Enalaprilat and Enalapril vs. Pretreatment baseline was evaluated on Forearm blood flow response to acetylcholine (endothelium-dependent vasodilation) (p=<0.001). Four weeks of oral enalapril therapy significantly improved endothelium-dependent vasodilation in type I diabetic patients, increasing forearm blood flow by 277% compared to 136% at baseline (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: